Acquisitions (Tables)

12 Months Ended

Mar. 31, 2013

Bios

The following reflects our allocation of the consideration, subject to customary purchase price adjustments in accordance with the Bios Agreement (in thousands):

Cash consideration	$	16,660
Contingent purchase price liability	2,140
Aggregate consideration	$	18,800

The purchase price was allocated as follows:
Accounts receivable, net	$	478
Inventories, net	910
Other current assets	28
Property, plant and equipment	63
Intangible assets	8,200
Goodwill	9,190
Current liabilities	(69		)
Total purchase price allocation	$	18,800

Schedule of pro forma effects of the acquisition on the results of operations

The pro forma effects of the acquisition on the results of operations as if the acquisition had been completed on April 1, 2012, 2011 and 2010, are as follows (in thousands, except per share data):

	Year ended March 31,
	2013		2012		2011
Total revenues	$	47,216	$	46,498	$	40,496
Net income	8,471		8,102		6,349
Net income per common share:
Basic	$	2.52	$	2.47	$	1.97
Diluted	2.36		2.34		1.91

Apex Laboratories, Inc.

Acquisition

Schedule of purchase price allocation

The purchase price allocation was as follows (in thousands):

Accounts Receivable, net	$	544
Inventories, net	65
Property and equipment	49
Intangible assets	4,571
Goodwill	1,261
	$	6,490

SGM Biotech, Inc.

Acquisition

Schedule of purchase price allocation

The purchase price allocation was as follows (in thousands):

Accounts receivable, net	$	1,116
Inventories, net	758
Other assets	195
Property and equipment	1,035
Liabilities	(1,021		)
Deferred tax liability	(2,358		)
Intangible assets	5,434
Goodwill	6,924
	$	12,083

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References+ Details